ArticlePharmacoEconomics2016

Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene.

Hedwig M Blommestein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.